EU Puts Spotlight On $21B J&J-Synthes Merger

Law360, New York (November 4, 2011, 2:03 PM EDT) -- Europe's chief regulator will investigate the potentially anti-competitive implications of the $21.3 billion merger between pharmaceuticals giant Johnson & Johnson and medical device maker Synthes Inc., the agency announced Friday.

The European Commission said its antitrust unit would conduct an in-depth investigation into whether the planned merger would stifle competition in the orthopedic devices market.

“The proposed acquisition would remove a competitor from some markets which are already concentrated,” Commission Vice President Joaquin Almunia said. “The commission needs to make sure that effective competition is preserved,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.